On May 10, 2013, Crawford, James John; Ortwine, Daniel Fred; Wei, Binqing; Young, Wendy B. published a patent.Recommanded Product: 87486-34-8 The title of the patent was Heteroarylpyridone and azapyridone compounds as inhibitors of BTK activity and their preparation. And the patent contained the following:
The invention relates to heteroarylpyridone and azapyridone compounds of formula I and stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathol. conditions, are disclosed. Compounds of formula I wherein X1is CR1 and N; X2 is CR2 and N; X3 is CR3 and N, where one or two of X1 – X2 are N; R1, R2 and R4 are independently H, F, Cl, NH2, etc.; R4 is H, F, Cl, CN, CH2OH, etc.; R5 is (un)substituted C6-20 aryl, C3-12 carbocyclyl, C1-20 heteroaryl, etc.; R6 is H, Me, Et, etc.; R7 is (un)substituted tricyclic azacyclyl; Y1 and Y2 are independently CH and N, provided that not both of Y1 and Y2 are N; and stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their BTK inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 0.132 μM. The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Recommanded Product: 87486-34-8
The Article related to heteroarylpyridone azapyridone preparation btk inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 87486-34-8